An epileptic seizure has been defined as a sudden alteration of central nervous system (CNS) function resulting from a high-voltage electrical discharge. This discharge may arise from an assemblage of neurons in either cortical or subcortical tissues. The spread of this excitatory activity to the subcortical, thalamic, and brainstem centers corresponds to the tonic phase of the seizure and loss of consciousness (1). In contrast, myoclonic activity refers to a series of rhythmic or arrhythmic muscular contractions (2). Depending on the electroencephalographic (EEG) findings, myoclonus is divided into epileptic and nonepileptic activity (3). Nonepileptic myoclonus originates from the brainstem or spinal cord and is due to either loss of cortical inhibition (4) or to impaired function of spinal interneurons (3,5). Without EEG monitoring, it is extremely difficult to determine whether abnormal-appearing seizurelike muscle movements are due to epileptiform activity or nonepileptic myoclonia.
Many anesthetic and analgesic drugs have been reported to cause seizure activity clinically (Table 1,  A) . Interestingly, many of these same drugs have also been shown to possess anticonvulsant properties (Table 1, B). In an effort to explain deficiencies with Guedel's original stages of anesthesia, Winters and colleagues ( 6 7 ) proposed a multidirectional continuum of anesthetic states ( Figure 1 ). For example, some agents (e.g., diethyl ether) traverse both CNS excitation (stages I, 11) and depression (stage 111). Others (e.g., halothane, ultrashort acting barbiturates) progress directly from stage I to 111, whereas still others (e.g., nitrous oxide [N,O], enflurane, ketamine, and narcotics [S]) induce a stage I1 cataleptoid CNS excitation, which on occasion progresses to myoclonia or generalized convulsions. Based on EEG studies in cats, Winters suggested that both excessively disorganized (stage 11) and decreased reticularformation activity (stage 111) result in unresponsiveness to painful stimuli and amnesia, consistent with the anesthetic state. Although both epileptic and anesthetic states possess similar features regarding arousal and memory, the categorization proposed by Winters fails to adequately explain the actions of those anesthetics that appear to possess both proconvulsant and anticonvulsant properties (Table 1) . For example, ketamine, an alleged stage I1 anesthetic which Winters believed to be contraindicated in epilepsy, has been successfully used to terminate status epilepticus (9, lo), and conversely, methohexital, a stage 111 agent, has been used in the diagnostic activation of epileptogenic foci (11, 12) .
To properly categorize the various anesthetic agents with respect to their effects on the seizure threshold, there are several important factors to consider. The first consideration is the patient population studied. For example, methohexital, in its current formulation (Brevital; Eli Lilly, Indianapolis, Ind.), will only produce epileptiform activity in patients with known seizure disorders (11, 12) . A second factor to consider is the method of proconvulsant and anticonvulsant documentation. This had led to confusion in the literature regarding the effects of some anesthetics and analgesics on CNS activity. Fentanylinduced seizures have been described clinically without the support of EEG documentation (13) (14) (15) . In some instances, these convulsivelike muscle movements may be due to nonepileptic myoclonus.
For most drugs used in anesthesia, subsequent EEG evaluation during their administration has helped to clarify whether or not a particular agent is truly epileptogenic in patients. However, for certain anesthetics, such as ketamine (16), the origin of epileptiform activity involves subcortical neuronal pathways. In humans, subcortical seizures are detected only with implanted EEG depth electrodes, not by standard surface leads. Thus, a third important factor to consider in determining whether or not an anesthetic possesses proconvulsant or anticonvulsant properties is the type of EEG recording electrodes (surface or depth) used during its evaluation.
In this review article, we have attempted to analyze the evidence for proconvulsant and anticonvulsant activity of anesthetics and analgesics. This information has been evaluated with respect to (a) patient population (epileptic or nonepileptic); (b) documentation of pro-and anticonvulsant activity (EEG study or clinical report); and (c) method of EEG analysis (surface or depth electrodes).
Inhala tion Anesthetics Volatile Agents
Enflurune. Abnormal movements consisting of twitching of individual muscle groups, and even tonic-clonic activity, were frequently observed during the early clinical evaluation of enflurane (17, 18) . Subsequent EEG recordings in normal patients demonstrated epileptiform activity (19, 20) and grand ma1 seizure patterns (21) ( Table 2) . These findings with enflurane have also been confirmed in patients with temporal lobe epilepsy during both electrocortico- (Figure 2) . In contrast to other volatile anesthetics, these burst suppression patterns are thought to represent an excitatory event
The ability of enflurane to produce seizure or EEG spiking activity is influenced by both its concentration and the Paco, (25,28). At a normal Paco, level, spiking is maximal at inspired enflurane concentra-
(29).
tions of 2%-3%. Higher Paco, concentrations reduce spiking activity (22). Interestingly, N,O does not affect the tendency of enflurane to produce spiking activity (28). With an alveolar enflurane concentration between 2.5% and 3%, hyperventilation to an average Paco, of 22 torr produced an increase in the frequency, magnitude, and synchrony of the spiking activity in epileptics (25). This technique has since been used to activate silent epileptogenic foci intraoperatively, to delineate the site of seizure activity before discrete surgical excision (23,24).
Conversely, with an enflurane concentration of 3.5%, the addition of CO, to the inhaled gas produced a decrease in magnitude and frequency of spiking activity (25). At an end-tidal CO, of 91 torr, spiking was not observed despite the fact that the enflurane alveolar concentration was increased to 4%. The rela tionship between enflurane concentration, Paco,, and epileptiform activity was further evaluated in a volunteer study that demonstrated that the minimum epileptogenic enflurane concentration was approximately 1% lower when the Paco, was 20 torr (vs normocarbia), and 1% higher when Paco, was 60 torr (26).
Postoperative seizure activity related to enflurane administration has also been reported, primarily in nonepileptic patients. These seizures may occur in the immediate postanesthetic period (30-33), within hours of surgery (34), and possibly as long as 3-9 days later (35,36). In a few instances the patients were either epileptic (33) or had a familial history of seizure disorders (36). In other reports, only transient (37,38) or prolonged (39) mvoclonic activity has been observed in otherwise conscious patients after enflurane. Whether or not these reports of postoperative seizurelike activity in normal patients are truly related to enflurane administration is unclear. Transient surface EEG spike (30) or seizure (23,36) activity has been reported postoperatively, which was absent on follow-up EEG studies. However, in volunteers exposed to 9.6 MAC hours of enflurane, only diffuse nonepileptiform EEG changes were observed using surface electrodes for 6-30 days after anesthesia (40). Half of these volunteers had exhibited both clinical and EEG seizure activity during enflurane anesthesia. In an animal study (41), high-amplitude spikes were recorded from depth electrodes in the thalamus for up to 15 days after exposure to enflurane. Therefore, one cannot exclude the possibility that after enflurane anesthesia there is actual subcortical epileptiform activity.
Various drugs have been reported to either enhance enflurane-induced spiking activity or lower its threshold. Both diazepam (30) and small doses of thiopental (42) were found to intensify enfluraneinduced seizures in humans. Larger doses of thiopental diminished seizure activity. In cats, enhanced enflurane-induced seizure activity has been demonstrated with the concomitant administration of diazepam, thiopental, methohexital, ketamine (43), and scopolamine (26). Conversely, in dogs, scopolamine significantly decreased enflurane-induced spiking activity (44). This may represent species variability to the CNS effects of scopolamine. Using depth electrodes in cats, Darimont and Jenkins (43) demonstrated that diazepam lowered the threshold for spiking activity by producing a leftward shift in the curve relating spiking frequency and enflurane concentration. In view of these contrasting findings, it remains unclear whether diazepam or thiopental should be used to treat perioperative seizures associated with enflurane anesthesia.
A variety of studies in animals have examined the mechanism of enflurane-induced hyperexcitability . It is unclear as to whether enflurane induces epileptogenic activity by inhibiting synapses (43,45) or by stimulating excitatory neuronal transmission (46). In investigations performed on cats with depth electrodes, it was reported that the seizure activity originated from the limbic system (amygdala and hippocampus) and midline thalamic nuclei (26,43,46). The subcortical origin for the epileptogenic properties of enflurane was further supported by the finding in rats that local cerebral glucose use (LCGU) in the limbic system was preserved or increased, whereas LCGU in many other structures was significantly decreased during deep enflurane anesthesia (47). However . Furthermore, in a recent study in rats (52), the authors suggested that intercortical and corticothalamic pathways are metabolically activated during enflurane seizure activity. In more than 300 patients with seizure disorders, the frequency of convulsivelike EEG activity during enflurane anesthesia was less compared with the previous sleep and awake EEGs of these epileptics (53). Furthermore, enflurane has been reported to inhibit seizure activity arising from epileptogenic foci (54,55). In animals, enflurane suppresses convulsions induced by electroshock, pentylenetetrazol, bicuculline, and penicillin (56,57). In amygdaloid-kindled cats, it was reported that both low (1.5%) and high (3.5%) concentrations of enflurane suppressed seizure activity (57). In children, successful termination of status epilepticus has been demonstrated with 1990;70303-15 enflurane (53) ( Table 3 ). The disappearance of EEG seizure activity was evident 20 min after induction and no further convulsive activity was noted during recovery. Despite these anticonvulsant findings, enflurane has a propensity for inducing epileptiform activity during anesthesia, especially when high concentrations are administered in the presence of hypocarbia.
Halothane. Halothane alone has not been reported to cause convulsions in humans (Table 2) . In the few reports (58,59) of halothane-related seizures, N20 was also administered. Electroencephalographic monitoring in normal patients had not revealed epileptiform activity during halothane anesthesia (60-62). However, nonspecific EEG slowing and rare sharp wave activity (attributed to the persistence of halothane and its metabolites) was seen in volunteers during the first week after 13-14 MAC-hours of halothane administration (60). In three epileptic patients, brief periods (<7 s) of bilateral atypical and polyspike waves were noted during emergence from halothane, but were not associated with clinical seizure activity during the perioperative period (63). Mild transient clonus has been observed after halothane anesthesia (37). Epileptic activity has been reported in cats given a high concentration of halothane (7%); however, cerebral blood flow and metabolism is also markedly altered at this concentration (64). Although depth electrodes have revealed occasional hippocampal spikes in cats (46), evoked spikes were not detected during halothane anesthesia in dogs subjected to loud hand-clapping in the presence of hypocapnia (65).
Inhaled anesthetics, including halothane, have been recommended for treatment of continuous seizures refractory to conventional intravenous anticonvulsant agents (66). Successful termination of resistant status epilepticus in children has been demonstrated with halothane (53) ( Table 3) . In these cases, the disappearance of spikes and waves was evident within 20 min. No seizures were noted after recovery. These potent anticonvulsant effects combined with the lack of clinically important cerebral excitatory findings for halothane would suggest that it does not possess proconvulsant properties.
Isoflurune. When administered alone, isoflurane has not been found to cause EEG or clinical seizure activity in anesthetized patients ( Table 2 ). In the reported cases of isoflurane-related seizures (67-69), N,O was also administered. In two of these cases, abnormal myoclonic movements starting intraoperatively and lasting into the early postanesthetic period were the only evidence of seizure activity (67,68).
Furthermore, one of these patients was conscious throughout the recovery period (67). In contrast to the reported convulsions after enflurane (23, 30, 36) , the postoperative EEG was normal in both reports. Alternative explanations for these seizurelike movements include nonepileptic myoclonus (3, 70) and/or the so-called withdrawal phenomena from N20 (71,72).
In another case report (69), isoflurane-N,O anesthesia was associated with tonic-clonic activity early during inhalational induction on two separate occasions. Before the second anesthetic, EEG studies were entirely normal. With EEG monitoring during the second induction, spike and wave forms were recorded during the clinical seizure and both ceased after administration of thiamylal. In this case, the finding that the spiking activity appeared with induction but did not continue during maintenance or reappear during recovery implies that N,O may have precipitated the seizure activity (73). Furthermore, N 2 0 alone has been associated with clinical seizures during induction (58,64), whereas isoflurane's anticonvulsant properties may have prevented further seizures during the maintenance and recovery periods (73,74).
In unpremedicated volunteers, induction of isoflurane anesthesia is characterized by low-voltage fast EEG activity that progresses toward high-voltage slow wave activity at 1 MAC. Bursts of slow highvoltage activity separated by electrical silence are noted at 1.5 MAC, with electrical silence at 2 2 MAC (75-77). Epileptic or spiking patterns do not appear, nor can they be evoked by lowering the Paco, or by introduction of auditory and visual stimuli (75, 77) . unpremedicated volunteers did not demonstrate clinical or EEG evidence of seizure activity during isoflurane-N20 inhaled induction (77). In premedicated patients undergoing inhaled induction with isoflurane and N,O (78), spikelike wave complexes lasting 1-2 s were seen when end-tidal isoflurane was increased above 2.5% and end-tidal CO, was intentionally lowered. In c'its (79, 80) , isoflurane was associated with high-voltage synchronous spikes but not seizures. In dogs subjected to loud hand-clapping in the presence of hypocapnia (65), isoflurane caused spontaneous spiking without seizure activity. It is unknown whether or not isoflurane, with or without N,O, will activate epileptogenic foci in patients with preexisting seizure disorders. However, seizurelike movements have not been reported during isoflurane anesthesia in epileptic patients.
Isoflurane has well-characterized anticonvulsant properties. In animals, isoflurane produced complete suppression of drug-induced convulsions (81) (82) (83) (84) . In patients with status epilepticus resistant to conventional therapy, isoflurane-0, produced rapid cessation of seizures with a burst suppression pattern at inspired concentrations ranging from 0.5% to 3.0% (74, 82, 83, 85) (Table 3) . When isoflurane was discontinued after exposures lasting 1-54 h, seizures recurred in 50% of the patients studied. These reports combined with the absence of EEG and clinical seizure activity during studies of its administration alone indicate that isoflurane is a potent anticonvulsant in humans.
lnvestigatioiial volatile agents. Sevoflurane and desflurane (1-653) are newly synthesized volatile anesthetics that are structurally similar to enflurane and isoflurane. The low solubility of both agents makes them potentially usetul when rapid awakening is desired (e.g., outpatient anesthesia) (86, 87) . In unpremeditated volunteers, successive incremental inspired sevoflurane doses of 1%, 2%, and 4% produced EEG patterns that contrasted with those commonly observed during the administration of most anesthetics (86). In light planes, an increase in both frequency (10-14 Hz) and amplitude, associated with unconsciousness, was observed in all subjects receiving sevoflurane. At deep levels, slower, lowvoltage, 5-8-Hz activity also appeared; however, the predominant 10-14-Hz activity persisted with a further increase in amplitude. Interestingly, a separate exposure of the same volunteers to an initial inspired sevoflurane concentr'i tion of 4% initially produced high-amplitude, rhythmic slow waves (2-3 Hz) that coincided with loss ot consciousness (86). The latter EEG pattern was dominant for 2-3 min, and then was replaced by a pattern identical to that observed during exposure to a lower concentration of sevoflurane. These findings are opposite to the traditional view that the greater the arterial blood level of anesthetics, the slower the EEG activities. No EEG or motor evidence of seizure activity has been reported during anesthesia with sevoflurane (Table 2) . It is unknown whether or not sevoflurane will activate epileptogenic foci in patients with preexisting seizure disorders.
Recently, EEG activity during anesthesia with desflurane was compared with isoflurane and enflurane in swine (87) . In this report, desflurane produced EEG waveforms and quantitative EEG values almost identical to those of isoflurane at equipotent concentrations. At low end-tidal concentrations (0.8 MAC) of desflurane, paroxysmal fast activity was occasionally noted. Higher concentrations produced progressive slowing of the EEG, and isoelectricity was observed at 1.6 MAC. No EEG or motor evidence of seizure activity was noted during desflurane administration. Furthermore, when these animals were exposed to either hypocapnia or external auditory stimuli, they did not demonstrate seizure activity during either desflurane or isoflurane anesthesia. In contrast, EEG and motor seizures occurred during hypocapnia with and without auditory stimuli in animals given 3.2% enflurane. The EEG effects of desflurane have not been investigated in humans. It is also unknown if sevoflurane and desflurane possess anticonvulsant properties. Further studies regarding the effects of these new volatile agents on CNS electrical activity in humans are clearly needed.
Nitrous Oxide
Animal studies would suggest that N,O stimulates brain metabolism when combined with other anesthetics (88-91). Withdrawal convulsions have been described in mice after short exposures to both normobaric (0.6-0.9 atm) and hyperbaric (1.2-1.6 atm) N,O (92, 93) . Volunteers exposed to hyperbaric (1.5 atm) N,O exhibited muscle rigidity, jerking movements, and occasional hyperactivity alternating with apparent relaxation (94). In contrast, mice exposed to high pressures of helium and/or 100% 0, did not display convulsions when removed from these gases (93) .
Hypersynchronous epileptoid EEG activity and an increase in reticular-formation neuronal activity was reported during N,O anesthesia in cats studied with depth electrodes (95). However, EEG studies performed in patients receiving N,O alone have not revealed seizure activity ( exhibited restlessness and hallucinations, whereas the nonepileptics remained unresponsive to stimuli. Although no convulsionlike withdrawal phenomena were reported, the fast EEG activity persisted for up to 1 h after discontinuation of N 2 0 (96) . In volunteers, diffuse paroxysmal bursts of high-voltage theta activity were observed immediately after cessation of N,O 30% (71). There appears to be only one case report, without EEG documentation, in which N 2 0 alone precipitated convulsions (Table 2) . In a child who convulsed during a halothane-N,O induction, subsequent inductions with halothane alone did not precipitate a seizure, whereas use of N,O alone was associated with seizurelike movements (58,64).
N,O alone has never been demonstrated to possess anticonvulsant properties in humans ( Table 3) . In one patient with refractory convulsions, 60% N 2 0 alone slowed but did not eliminate tonic-clonic or EEG seizure activity (85) . In animals, N,O was found to elevate the local anesthetic seizure threshold (97) and to reduce the frequency of EEG spiking activity during enflurane anesthesia (98) . N 2 0 remains the oldest and most widely used anesthetic in clinical practice. In view of this long-standing record of safety and the available evidence regarding its cerebral stirnulatory effects, its epileptogenic potential appears to be extremely low.
Intravenous Analgesics Opioid (Narcotic) Analgesics
Meperidine. Meperidine neurotoxicity is well known and is manifest clinically as shakiness, tremors, myoclonus, and seizures (99) (Table 4). This neuroexcitement is attributed to its N-demethylated metabolite normeperidine (100,101). The half-life of normeperidine (14-21 h) is significantly longer than that of meperidine ( 3 4 h). Thus, with repeated or continuous meperidine administration, normeperidine can accumulate, leading to neurotoxicity (99) (100) (101) . The risk of precipitating convulsions is theoretically greater with chronic oral administration because it produces lower meperidine and higher normeperidine blood levels due to extensive firstpass metabolism (102). However, seizures have occurred after both chronic oral (99,103) and intramuscular (100,104) administration. Myoclonus generally precedes the seizures, and both resolve over several days with discontinuation of meperidine administration (101, 103) .
Anticonvulsants (e.g., phenytoin [ 1051, phenobarbital [106] ) and phenothiazines (e.g., chlorpromazine [107] ) have been demonstrated to increase the conversion of meperidine to normeperidine in humans. In mice, concomitant administration of promethazine and meperidine has been shown to be synergistic in inducing seizures (108) . Concomitant therapy with either anticonvulsants (103) or phenothiazines (104,109) may have been a contributing factor in some reports of seizure activity after oral or parenteral meperidine administration.
The EEG pattern after intravenous administration of a single high dose (400 mg) of meperidine is characterized by primarily high-voltage delta waves, similar to that reported for other narcotics (110) . However, in otherwise healthy patients in whom seizures occurred after repeated meperidine administration, EEG studies have revealed diffuse slow ANESTH ANAl G 1 W0;70: 30% 15 MODICA ET AL. activity and epileptiform discharges (99,111) (Table 4).
Patient subgroups that appear to be more susceptible to the neurotoxicity associated with chronic meperidine therapy include (a) patients with renal failure in whom the normeperidine half-life is prolonged (34 h) due to decreased metabolism and excretion (100,103), and (b) patients with advanced malignancy (100,101) or sickle cell anemia (112), both of whom receive progressively larger doses of meperidine due to the development of tolerance. Seizurelike movements have not been reported in epileptic patients during either acute or chronic meperidine administration. Furthermore, it is unknown whether or not acute or chronic meperidine use will activate epileptogenic EEG foci in patients with preexisting seizure disorders.
Meperidine has demonstrated the lowest safety margin for convulsions of all narcotics studied. In dogs, EEG seizure activity was induced with an average intravenous rneperidine dose (20 mg/kg) that was only 2.2 times greater than the mean effective intravenous dose (9 mg/kg) for surgical analgesia (8). In mice, naloxone can only partially block the convulsions induced by normeperidine, whereas meperidine-induced seizures are completely blocked by prior administration of naloxone (113) . Neither meperidine nor normeperidine has ever been shown to possess anticonvulsant properties. Within the range of meperidine doses used clinically to supplement general or regional anesthetic techniques, the proconvulsant effects of the drug appear to be of little concern. However, seizures may result from normeperidine accumulation after prolonged meperidine administration (e.g., patient-controlled analgesia), especially in patients with renal failure, sickle cell, and cancer.
Morphine. Morphine alone has never been demonstrated to produce stlizure activity in humans after intravenous administration. High-dose morphine (1-2 mg/kg, IV) during open-heart surgery was associated with progressive slowing of EEG activity and an increase in low-frequency amplitude. No epileptiform activity was noted (114). Electroencephalographic investigations have not been performed in epileptic patients during high-dose morphine administration. However, A tonic-clonic seizure was reported after administration of epidural morphine to a known epileptic (115) ( Table 4) . There was a 6-h delay between epidural administration and the onset of seizure, consistent with the known kinetics of morphine in the cerebrospinal fluid (116, 117) . A convulsion has also occurred after intrathecal morphine in a nonepileptic cancer patient (118) . These reports suggest a subcortical origin for morphine-induced seizures. Electrophysiologic studies in rats support this concept as morphine causes disinhibition of the pyramidal cells of the hippocampus, leading to seizure discharges (119) . A grand ma1 seizure in a 14-yr-old boy occurred 90 min after 20 mg of intramuscular morphine and 0.4 mg of scopolamine were administered (120) . A prodrome of intense itching was experienced by the patient, indicating that morphine probably contributed to the seizure activity, although the well-known excitatory CNS effects of scopolamine may have been an additional contributing factor in this case. Withdrawal seizures have been reported clinically, predominantly in neonates born to heroinaddicted mothers (121) .
DeCastro et al. (8) found that an average morphine dose of 180 mg/kg, IV, was required to precipitate EEG seizure activity in dogs. This was 72 times greater than the mean effective intravenous dose (2.5 mg/kg) for surgical analgesia. In rats, higher systemic doses of morphine produce epileptiform patterns and behavioral convulsions that are not reversed by opiate antagonists (122) . Seizures have also been demonstrated after intracerebroventricular administration of morphine in rats (123,124) and after intrathecal administration of morphine in dogs (125) and rats (126). Although the cerebroventricular-induced seizures are naloxone reversible (124) , the intrathecal morphine-induced tonic-clonic movements were not naloxone reversible (126) . These findings suggest that the proconvulsant actions of high doses of morphine in animals are mediated by both opiate (e.g., mu) and nonopiate (e.g., y-aminobutyric acid) receptor mechanisms (122, 127) .
Morphine alone has never been demonstrated to possess anticonvulsant properties in humans. In rabbits, intravenous morphine terminated bicucullineand picrotoxin-induced EEG and behavioral seizures (127) . In rats, intravenous morphine delayed the onset of pentylenetetrazol-and flurothyl-induced seizures (122) . Although intravenous morphine in high doses has both pro-and anticonvulsant properties in animals, the doses of the drug used in clinical practice appear to have little effect on the seizure threshold. This is especially true with noncerebrospinal fluid routes of morphine administration.
Fenfanyl and its analogues. There have been several reports of grand ma1 seizure-like motor behavior in patients after administration of low (1OC-200 pg) (14, 15, 128, 129) to moderate (2250-2500 pg) (13, 130) doses of intravenous fentanyl. This phenomena has also occurred after sufentanil (40-150 pg, IV [131, Abnormal motor activity resembling epileptic convulsions has occurred in the absence of cortical seizure activity on simultaneous EEG recordings made during low-dose (500-600 pg, IV) fentanyl (132,142) and sufentanil (1.3 pglkg, IV) (143) administration. Yet, seizurelike movements were not observed during EEG studies in patients treated with high doses of fentanyl and its analogues. There are several possible explanations for these observations. The abnormal movements observed after low-to-moderate doses of fentanyl or sufentanil could be due to nonepileptic myoclonus produced by the interaction of these narcotics with opiate receptors leading to blockade of cortical inhibitory pathways. This would allow lower CNS centers in the brainstem and/or spinal cord to display altered excitability (4,142). Patients treated with higher doses of fentanyl and its analogues may have failed to exhibit these seizurelike myoclonic movements because the plasma opioid levels were high enough to depress both higher and lower CNS centers. In one report, nonepileptic myoclonus was probably responsible for the seizurelike motor activity observed after recovery from low-dose fentanyl administration (128). In addition, this patient also received etomidate, an anesthetic that produces nonepileptic myoclonic activity (144), which occasionally persists into the postoperative period (145,146) .
An alternative explanation is that these movements represent an exaggerated form of narcoticinduced rigidity (142). Rigidity can occur after low doses of fentanyl (147) and high-dose alfentanil inductions have produced rigidity involving all extremities that closely resembles seizures in volunteers (148). Recent studies have suggested that rigidity may involve neurochemical mechanisms in the striatonigral pathways similar to Parkinson's disease (149-151) . Thus, exaggerated rigidity could have been responsible for the seizurelike movements observed after low-dose sufentanil administration (131). In these two cases, one patient had a history of Parkinson's disease, and the other patient was receiving chronic metoclopramide therapy. Metoclopramide inhibits cerebral dopaminergic pathways and can produce extrapyramidal signs (152,153) .
The tonic-clonic movements reported with administration of low-to-moderate doses of fentanyl and sufentanil could also be due to subcortical seizure activity. Electroencephalograph-documented cortical seizures have been induced by high-dose fentanyl (8,154,155) and sufentanil (156) in animals. The EEG seizures in rats were accompanied by decreases in LCGU in cortical structures and relative increases in LCGU in the subcortical limbic system (hippocampus, amygdala, claustrum) (154,155), an area rich in opioid receptors. In humans, subcortical seizures are not detected by surface EEG leads, and EEG studies with depth electrodes are required to confirm or reject the hypothesis that fentanyl and sufentanil cause seizures in humans (155).
Fentanyl and its analogues alone have never been demonstrated to possess anticonvulsant properties in either humans or animals. However, during fentanyl administration with droperidol and N,O (neuroleptanesthesia), EEG monitoring in epileptic patients did not demonstrate an increase in spiking activity compared with their baseline EEG studies (53). In a study of 104 patients receiving neuroleptanesthesia, no EEG or clinical signs of seizures were observed during or after neuroradiologic examinations with intrathecal metrizamide, a known convulsant (141). As suggested by DeCastro et al. (8), these findings appear to indicate that droperidol may offer some protection against narcotic-induced neuroexcitation.
Whether the seizurelike movements reported during clinical administration of fentanyl and its analogues originate from epileptogenic or nonepileptogenic mechanisms is unclear. All currently available clinical and EEG evidence appears to favor either nonepileptic myoclonus or exaggerated rigidity as the most likely explanation. However, further studies regarding the neurochemical mechanisms of narcoticinduced rigidity and the effects of progressively higher doses of fentanyl and its analogues on electrical activity in the limbic system are needed.
Summary
Many inhaled anesthetics and intravenous analgesics have been alleged to produce both proconvulsant and anticonvulsant activity in humans ( Table 1) . The reasons for these contrasting actions on the CNS are poorly understood at the present time. However, biologic variability plays an important role in determining individual patient's responses to anesthetic and analgesic drugs. In addition, variations in the responsiveness of inhibitory and excitatory neurons to the central depressant effects of these drugs could also explain these apparently conflicting data. Depending on the brain concentration, centrally active drugs may produce differing effects on the CNS inhibitory and excitatory neurotransmitter systems. The availability of increasingly powerful magnetic resonance imaging techniques to provide noninvasive information about tissue chemistry (e.g., neurotransmitters and citric acid cycle metabolites) and positron emission tomography to noninvasively evaluate CNS drug-receptor interactions should lead to a more in-depth understanding of the in vivo effects of anesthetics and analgesics on the CNS.
In the second part of this review article, we discuss the pro-and anticonvulsant effects of the sedativehypnotics, local anesthetics, and other anesthetic adjuvant drugs. 
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